[Money Today] AMCG won the top prize at the "Seoul-Financial Investment Association (K-OTC) Joint Scale-Up IR" event. > News


IR/PR All-in-one Heart Disease Diagnostic Solution

News

[Money Today] AMCG won the top prize at the "Seoul-Financial Investment Association (K-OTC) Joint Scale-Up IR" event.

Writer 최고관리자

Date 2025.09.17

119

AMCG won the top prize at the "Seoul-Financial Investment Association (K-OTC) Joint Scale-Up IR" event.


☞ Go to article


AMCG (CEO Seo Yong-seong) announced on the 17th that we received the top prize at the ‘Seoul Metropolitan Government - Korea Financial Investment Association (K-OTC) Joint Scale-up IR’.


The ‘Joint Scale-up IR’ is an event hosted by the Seoul Metropolitan Government and the Korea Financial Investment Association (K-OTC) to support promising companies with high growth potential in securing funding. An IR presentation was conducted for a panel of 10 judges, including securities firms, asset management companies, and venture capital (VC) firms. After evaluation in the areas of organizational capability, marketability, technological capability, and business viability, AMCG was selected as the top company.


AMCG is a startup advancing commercialization in the next-generation cardiac disease diagnostics field based on quantum sensors and AI. AMCG's MCG(Magnetocardiograph) scan system incorporates the world's highest-channel count (96ch) configuration of world-leading superconducting quantum interference device (SQUID) sensors. Furthermore, by utilizing AI technology to eliminate environmental magnetic noise and enhance diagnostic algorithms, it has been developed as a medical device optimized for the early diagnosis of ischemic heart disease.


MCG scan enables measurement through a completely non-invasive method without contrast agents or radiation exposure. It is recognized as an innovative technology that ana lyzes the heart's electrophysiological data to determine the presence of cardiac disease. With the product now launched in the largest markets, the United States and China, and numerous clinical trials underway, market interest is growing as a next-generation diagnostic device.


Seo Yong-seong, CEO of AMCG, stated that leveraging Seoul Metropolitan Government's institutional investor network and investment attraction support will provide tangible growth opportunities. He added that the company will continue to challenge itself in domestic and international markets alongside diverse partners.


서용성 에이엠시지 대표가 최우수상을 수상하고 있다/사진제공=에이엠시지
Seo Yong-seong, CEO of AMCG, is receiving the Grand Prize.

[Money Today Reporter Ban Jun-hwan]

go top